|
Name |
Rhizovarin E
|
Molecular Formula | C39H51NO5 | |
IUPAC Name* |
(2S,3R,6R,8R,9S,10R,12S,13S,16R,17S,21S,22S,24S)-22-(2-hydroxypropan-2-yl)-17-methoxy-2,3-dimethyl-25-methylidene-8-prop-1-en-2-yl-11-oxa-31-azanonacyclo[16.13.0.02,16.03,13.06,12.010,12.019,30.020,27.021,24]hentriaconta-1(18),19(30),20(27),28-tetraene-9,13-diol
|
|
SMILES |
CC(=C)[C@H]1C[C@H]2CC[C@@]3([C@@]4([C@@H](CC[C@]3([C@@]25[C@@H]([C@H]1O)O5)O)[C@@H](C6=C4NC7=C6C8=C(CC(=C)[C@@H]9[C@H]8[C@H](C9)C(C)(C)O)C=C7)OC)C)C
|
|
InChI |
InChI=1S/C39H51NO5/c1-18(2)22-16-21-11-13-36(6)37(7)24(12-14-38(36,43)39(21)34(45-39)31(22)41)32(44-8)30-29-26(40-33(30)37)10-9-20-15-19(3)23-17-25(35(4,5)42)28(23)27(20)29/h9-10,21-25,28,31-32,34,40-43H,1,3,11-17H2,2,4-8H3/t21-,22-,23-,24+,25+,28+,31+,32+,34-,36-,37-,38+,39+/m1/s1
|
|
InChIKey |
ULAVCJKSVMEGQI-GSHAFRTFSA-N
|
|
Synonyms |
Rhizovarin E
|
|
CAS | NA | |
PubChem CID | 139589622 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 613.8 | ALogp: | 5.0 |
HBD: | 4 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 98.2 | Aromatic Rings: | 9 |
Heavy Atoms: | 45 | QED Weighted: | 0.239 |
Caco-2 Permeability: | -5.373 | MDCK Permeability: | 0.00000849 |
Pgp-inhibitor: | 0.934 | Pgp-substrate: | 0.997 |
Human Intestinal Absorption (HIA): | 0.047 | 20% Bioavailability (F20%): | 0.787 |
30% Bioavailability (F30%): | 0.739 |
Blood-Brain-Barrier Penetration (BBB): | 0.922 | Plasma Protein Binding (PPB): | 89.68% |
Volume Distribution (VD): | 1.981 | Fu: | 5.54% |
CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.963 |
CYP2C19-inhibitor: | 0.032 | CYP2C19-substrate: | 0.76 |
CYP2C9-inhibitor: | 0.145 | CYP2C9-substrate: | 0.067 |
CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.169 |
CYP3A4-inhibitor: | 0.755 | CYP3A4-substrate: | 0.918 |
Clearance (CL): | 7.724 | Half-life (T1/2): | 0.023 |
hERG Blockers: | 0.967 | Human Hepatotoxicity (H-HT): | 0.577 |
Drug-inuced Liver Injury (DILI): | 0.656 | AMES Toxicity: | 0.019 |
Rat Oral Acute Toxicity: | 0.977 | Maximum Recommended Daily Dose: | 0.977 |
Skin Sensitization: | 0.147 | Carcinogencity: | 0.907 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.987 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001499 | 0.616 | D06AWE | 0.239 | ||||
ENC003330 | 0.579 | D0H2JP | 0.239 | ||||
ENC001508 | 0.528 | D06AEO | 0.219 | ||||
ENC001486 | 0.525 | D0KR9U | 0.218 | ||||
ENC001507 | 0.509 | D0I2SD | 0.215 | ||||
ENC003834 | 0.486 | D02IQY | 0.215 | ||||
ENC003329 | 0.466 | D04RYU | 0.213 | ||||
ENC001891 | 0.450 | D0X7XG | 0.212 | ||||
ENC003453 | 0.438 | D0M4WA | 0.212 | ||||
ENC003929 | 0.412 | D0J1ML | 0.212 |